<DOC>
	<DOCNO>NCT00851253</DOCNO>
	<brief_summary>RATIONALE : Stereotactic radiosurgery may able send x-ray directly tumor cause less damage normal tissue . PURPOSE : This phase I trial study side effect stereotactic radiosurgery treat patient locally advance recurrent head neck cancer .</brief_summary>
	<brief_title>Stereotactic Radiosurgery Treating Patients With Locally Advanced Recurrent Head Neck Cancer</brief_title>
	<detailed_description>OBJECTIVES : - To determine feasibility tolerability CyberKnife® stereotactic radiosurgery boost therapy standard chemoradiotherapy patient locally advanced head neck cancer . - To determine feasibility tolerability CyberKnife® stereotactic radiosurgery salvage therapy patient locally recurrent head neck cancer . OUTLINE : Patients assign 1 2 treatment group accord disease status prior standard therapy . Patients residual disease standard therapy assign group 1 . Patients recurrent disease ≥ 6 month standard therapy assign group 2 . All patient undergo placement 3-6 gold fiducial marker within 1-2 week begin CyberKnife® stereotactic radiosurgery ( SRS ) treatment . - Group 1 ( CyberKnife® SRS boost therapy ) : Patients undergo CyberKnife® SRS boost therapy ( 2 fractionate dos ) begin 4-8 week completion standard therapy . - Group 2 ( CyberKnife® SRS salvage therapy ) : Patients undergo CyberKnife® SRS salvage therapy ( 5 fraction ) 3 time weekly . After completion study treatment , patient follow periodically 2 year .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Biopsyconfirmed* invasive head neck cancer , include follow primary site : Nasopharynx Oropharynx Paranasal sinus Oral cavity Orbit Salivary gland NOTE : *Biopsy must perform prior initiation external beam radiotherapy ( EBRT ) Stage T24 tumor time diagnosis Primary tumor ≤ 5 cm diameter time CyberKnife® stereotactic radiosurgery ( SRS ) Meets one follow criterion : Eligible CyberKnife® SRS boost therapy , define one follow criterion : Planning undergo definitive EBRT , without chemotherapy , curative intent primary head neck cancer Biopsyconfirmed locally persistent disease &lt; 3 month completion definitive EBRT Eligible CyberKnife® SRS salvage therapy* , define one follow criterion : Biopsyconfirmed locally recurrent disease occur ≥ 6 month completion radiotherapy ; achieve complete response initial therapy image clinical examination ; &gt; 50 % tumor volume prior irradiated volume ; receive &gt; 45 Gy radiotherapy Biopsyconfirmed locally recurrent disease occur 6 week 6 month completion radiotherapy ; achieve complete response initial therapy image clinical examination ; &lt; 50 % tumor volume prior irradiated volume ; receive &gt; 45 Gy radiotherapy NOTE : *Not candidate salvage surgery brachytherapy Anticipated total dose radiotherapy spinal cord ≤ 50 Gy ( include prior dose ) PATIENT CHARACTERISTICS : Karnofsky performance status 60100 % Not pregnant nursing Fertile patient must use effective contraception Able achieve normal tissue tolerance critical structure CyberKnife® planning system Able undergo CT simulation PRIOR CONCURRENT THERAPY : See Disease Characteristics No laryngeal hypopharyngeal cancer No evidence distant metastases No prior brachytherapy No prior CyberKnife® SRS boost salvage therapy No malignancy within past 5 year except basal cell squamous cell skin cancer carcinoma situ cervix No active connective tissue disorder ( e.g. , lupus scleroderma )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>recurrent adenoid cystic carcinoma oral cavity</keyword>
	<keyword>recurrent mucoepidermoid carcinoma oral cavity</keyword>
	<keyword>recurrent verrucous carcinoma oral cavity</keyword>
	<keyword>stage II adenoid cystic carcinoma oral cavity</keyword>
	<keyword>stage II mucoepidermoid carcinoma oral cavity</keyword>
	<keyword>stage II verrucous carcinoma oral cavity</keyword>
	<keyword>stage III adenoid cystic carcinoma oral cavity</keyword>
	<keyword>stage III mucoepidermoid carcinoma oral cavity</keyword>
	<keyword>stage III verrucous carcinoma oral cavity</keyword>
	<keyword>stage II squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage III squamous cell carcinoma lip oral cavity</keyword>
	<keyword>recurrent basal cell carcinoma lip</keyword>
	<keyword>recurrent squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage II basal cell carcinoma lip</keyword>
	<keyword>stage III basal cell carcinoma lip</keyword>
	<keyword>recurrent lymphoepithelioma nasopharynx</keyword>
	<keyword>recurrent squamous cell carcinoma nasopharynx</keyword>
	<keyword>stage II lymphoepithelioma nasopharynx</keyword>
	<keyword>stage II squamous cell carcinoma nasopharynx</keyword>
	<keyword>stage III lymphoepithelioma nasopharynx</keyword>
	<keyword>stage III squamous cell carcinoma nasopharynx</keyword>
	<keyword>recurrent lymphoepithelioma oropharynx</keyword>
	<keyword>recurrent squamous cell carcinoma oropharynx</keyword>
	<keyword>stage II lymphoepithelioma oropharynx</keyword>
	<keyword>stage II squamous cell carcinoma oropharynx</keyword>
	<keyword>stage III lymphoepithelioma oropharynx</keyword>
	<keyword>stage III squamous cell carcinoma oropharynx</keyword>
	<keyword>high-grade salivary gland mucoepidermoid carcinoma</keyword>
	<keyword>low-grade salivary gland mucoepidermoid carcinoma</keyword>
	<keyword>recurrent salivary gland cancer</keyword>
	<keyword>salivary gland acinic cell tumor</keyword>
	<keyword>salivary gland adenocarcinoma</keyword>
	<keyword>salivary gland adenoid cystic carcinoma</keyword>
	<keyword>salivary gland anaplastic carcinoma</keyword>
	<keyword>salivary gland malignant mixed cell type tumor</keyword>
	<keyword>salivary gland poorly differentiate carcinoma</keyword>
	<keyword>salivary gland squamous cell carcinoma</keyword>
	<keyword>stage II salivary gland cancer</keyword>
	<keyword>stage III salivary gland cancer</keyword>
	<keyword>stage IV adenoid cystic carcinoma oral cavity</keyword>
	<keyword>stage IV mucoepidermoid carcinoma oral cavity</keyword>
	<keyword>stage IV squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage IV verrucous carcinoma oral cavity</keyword>
	<keyword>stage IV salivary gland cancer</keyword>
	<keyword>stage IV lymphoepithelioma nasopharynx</keyword>
	<keyword>stage IV lymphoepithelioma oropharynx</keyword>
	<keyword>stage IV squamous cell carcinoma nasopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma oropharynx</keyword>
	<keyword>stage IV basal cell carcinoma lip</keyword>
</DOC>